Company: BDRX
Filing Date: 2025-05-01
Form Type: DRS
Source: 0001214659-25-006756
Chunk: 149

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-05-01
Form: DRS
Chunk 149
---
 not apply to us; and                                                               |

| ● | it has complied and will comply with all applicable provisions                                                                    
 of the FSMA with respect to anything done by it in relation to the securities in, from or otherwise involving the United Kingdom. |

| 80 |

Switzerland.
The securities may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange (the SIX) or on any other stock
exchange or regulated trading facility in Switzerland. This document has been prepared without regard to the disclosure standards for
issuance prospectuses under art. 652a or art. 1156 of the Swiss Code of Obligations or the disclosure standards for listing prospectuses
under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility in Switzerland.
Neither this document nor any other offering or marketing material relating to the securities or the offering may be publicly distributed
or otherwise made publicly available in Switzerland.

Neither this document
nor any other offering or marketing material relating to the offering, or the securities have been or will be filed with or approved by
any Swiss regulatory authority. In particular, this document will not be filed with, and the offer of securities will not be supervised
by, the Swiss Financial Market Supervisory Authority FINMA, and the offer of securities has not been and will not be authorized under
the Swiss Federal Act on Collective Investment Schemes (CISA). Accordingly, no public distribution, offering or advertising, as defined
in CISA, its implementing ordinances and notices, and no distribution to any non-qualified investor, as defined in CISA, its implementing
ordinances and notices, shall be undertaken in or from Switzerland, and the investor protection afforded to acquirers of interests in
collective investment schemes under CISA does not extend to acquirers of securities.

Australia.
No placement document, prospectus, product disclosure statement or other disclosure document has been lodged with the Australian Securities
and Investments Commission (ASIC), in relation to the offering.

This prospectus
does not constitute a prospectus, product disclosure statement or other disclosure document under the Corporations Act 2001 (the Corporations
Act) and does not purport to include the information required for a prospectus, product disclosure statement or other disclosure document
under the Corporations Act.

Any offer in Australia
of the securities may only be made to persons (the Exempt Investors) who are “sophisticated investors” (within the meaning